Setipiprant
Setipiprant is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan. Reference standards of Setipiprant API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object
(
[pname] => Setipiprant
[catalogue_number] => PA 19 1600000
[category_ids] => ,75,76,78,70,82,
[chemical_name] =>
[weight] => 402.43
[form] => C24H19FN2O3
[cas] => 866460-33-5
[pslug] => 866460-33-5-setipiprant-api-pa191600000
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
Catalogue No.:PA 19 1600000
Molecular Formula : C24H19FN2O3
Molecular Weight : 402.43